Home > Journals > Panminerva Medica > Past Issues > Panminerva Medica 1999 March;41(1) > Panminerva Medica 1999 March;41(1):22-6

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions

 

ORIGINAL ARTICLES   

Panminerva Medica 1999 March;41(1):22-6

Copyright © 2000 EDIZIONI MINERVA MEDICA

language: English

Plasma endothelin-1 levels in patients with peripheral arterial occlusive disease at different Fontaine’s stages

Mangiafico R. A., Malatino L. S., Santonocito M., Sarnataro F., Dell’Arte S., Messina R., Santangelo B.

From the Institute of Internal Medicine “L. Condorelli”, University of Catania, Catania, Italy


PDF


Endothelin-1 (ET-1) is a ­potent vas­o­con­stric­tor and mit­o­gen­ic pep­tide pro­duced and secret­ed by endo­the­lial ­cells, ­which can ­play a poten­tial ­role in the devel­op­ment of ath­ero­scler­o­sis and in the pathoph­y­sio­lo­gy of extreme vaso­con­stric­tion of var­i­ous dis­eas­es.
Methods. To ­assess plas­ma endo­the­lin-1 (ET-1) con­cen­tra­tions in ­patients ­with periph­er­al arte­ri­al occlu­sive dis­ease (­PAOD) at dif­fer­ent Fontaine’s stag­es, we meas­ured plas­ma ET-1 by radio­im­mu­noas­say in 14 ­stage II ­PAOD ­patients (12 men, 2 wom­en; ­mean age 59.5±3.4 ­years) and in 10 ­stage III-IV ­PAOD ­patients (8 men, 2 wom­en, ­mean age 61.2±3.3 ­years). Ten nor­mal sub­jects (8 men, 2 wom­en, ­mean age 58.1±7.2 ­years) ­were con­sid­ered as con­trols.
Results. Mean (±SD) plas­ma ET-1 lev­els, as meas­ured by radio­im­mu­noas­say, ­were sig­nif­i­cant­ly great­er in ­stage II and ­stage III-IV ­PAOD ­patients ­than in con­trol sub­jects (4±0.4 and 5±0.4 ­pmol/L vs 2.5±0.6 ­pmol/L, respec­tive­ly, p<0.001). Furthermore, plas­ma lev­els of ET-1 in ­stage III-IV ­patients ­were sig­nif­i­cant­ly high­er ­than in ­stage II ­patients (p<0.01). A sig­nif­i­cant cor­re­la­tion was ­found ­between plas­ma ET-1 lev­els and num­ber of the arte­ri­al obstruc­tive ­lesions in ­PAOD ­patients (r=0.698; p<0.0001). No sig­nif­i­cant cor­re­la­tion was ­found ­between plas­ma ET-1 con­cen­tra­tions and ­pain-­free walk­ing dis­tance (r=-0.279, p=0.333, in ­stage II ­patients; r=0.137, p=0.705, in ­stage III-IV ­patients), and ­between plas­ma ET-1 lev­els and ­ankle/arm pres­sor ­index (r=0.032, p=0.913, in ­stage II ­patients; r=0.149, p=0.681, in ­stage III-IV ­patients) in the ­PAOD ­patients.
Conclusions. Raised plas­ma ET-1 ­could be a sen­sible mark­er ­both of endo­the­lial dam­age and dis­ease exten­sion. It ­could ­also pro­mote the pro­gres­sion of ath­e­ros­cle­rot­ic ­plaques and ­enhance the micro­vas­cu­lar resis­tance in ­these ­patients.

top of page